공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 면역글로불린 시장 : 성장, 동향, 예측(2020-2025년)

Immunoglobulin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 921912
페이지 정보 영문
가격
US $ 4,250 ₩ 4,788,000 PDF (Single User License)
US $ 4,750 ₩ 5,352,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 6,760,000 PDF (Site License)
US $ 7,500 ₩ 8,451,000 PDF (Corporate License)


세계의 면역글로불린 시장 : 성장, 동향, 예측(2020-2025년) Immunoglobulin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 면역글로불린(Immunoglobulin) 시장은 면역부전 질환의 유병률 상승, 면역글로불린의 채택 증가 및 고령자 인구의 급증에 의해 급성장할 것으로 예측됩니다. 바이오마커의 수요 증가, 양성 종양과 악성 종양의 보다 정확한 구별 가능에 의한 암진단 툴로서 공간 게놈 분석의 수요 증가에 의해 이 시장의 성장이 지원되고 있습니다.

세계의 면역글로불린 시장에 대해 조사했으며, 시장 기회 및 동향, 성장 및 저해요인, 제품·투여 방법·용도·지역별 시장 분석, 경쟁 구도, 주요 기업의 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

  • 조사 성과
  • 조사의 전제조건
  • 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
    • 면역부전증의 유병률 상승
    • 면역글로불린의 채택 증가
    • 고령자 인구의 급증
  • 시장 성장 저해요인
    • 엄격한 정부 규제
    • 높은 치료비
  • Porter's Five Forces 분석

제5장 시장 세분화

  • 제품별
    • IGG
    • IGA
    • IGM
    • IGE
    • IGD
  • 투여 방법별
    • 정맥내
    • 피하
  • 용도별
    • 저감마글로불린혈증
    • 만성 염증성 탈수초성 다발신경병증(CIDP)
    • 면역부전증
    • 중증근무력증
    • 특발성 혈소판 감소성 자반증(ITP)
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동·아프리카
    • 남미

제6장 경쟁 구도

  • 기업 개요
    • Baxter international Inc.
    • CSL Ltd.
    • Grifols SA
    • Octapharma AG
    • Kedrion Biopharma Inc.
    • LFB group
    • Biotest AG
    • China Biologics Products, Inc
    • Shire(Baxalta)
    • Bayer Healthcare

제7장 시장 기회 및 향후 전망

KSA 20.02.17

The Global Immunoglobulin Market was valued at approximately USD 11,575 million in 2020, and it is expected to reach USD 16,890 million in 2026 with a CAGR of 6.5% over the forecast period.

Globally, the outbreak of COVID-19 in 2020, was one of the greatest infectious challenges, in recent times. Currently, few treatment options exist, and the availability of vaccines in some countries. There is an urgent need for effective therapies in the treatment of patients with COVID-19 infection. The use of immunoglobulin in the treatment of COVID-19 infection can be effective in the management of the disease. For instance, according to a research study by Alan A. Nguyen et al. published in Clinical Immunology Journal 2020, the use of immunoglobulins in the treatment of COVID-19 is found to be effective, but not without potential adverse consequence.

The immunoglobulin market is expected to show rapid growth due to the rise in prevalence of immunodeficiency diseases, increase in adoption of immunoglobulin, and growing research and development activities.

The spatial patterns of the genome have been identified for treating several medical conditions, which has resulted in the implementation of spatial information as a diagnostic biomarker for various diseases. There is a growing demand for biomarkers, which enables differentiation of benign tumor from the malignant tumor with higher accuracy and therefore boosts the demand for spatial genomic analysis as a cancer diagnostic tool. Therefore the cumulative demand for robust cancer diagnostic solutions helps in the growth of the overall market.

Increasing research and development activities in the development of new products in the management of the diseases is expected to drive market growth. For instance, in January 2019, Kedrion Biopharma received United States Food and Drug Administration approval for conducting clinical trial to assess the efficacy and safety of a 10% intravenous immunoglobulin in the treatment of patients with primary immunodeficiency diseases (PID).

The market players are involved in the development of innovative drugs and discovering new therapeutic areas for the existing drugs. For instance, as per National Clinical Trial (NCT) Registry, in February 2020, in China, Peking Union Medical College Hospital in collaboration with Tongji Hospital of Tongji Medical College and Huazhong University of Science and Technology initiated a phase II/Phase III clinical trial to assess the efficacy and safety of intravenous immunoglobulin (IVIG) for severe 2019 novel coronavirus (2019-nCoV) pneumonia. However, factors such as stringent government regulations and high cost of therapy is expected to impede the market growth over the forecast period.

Key Market Trends

By Application, Hypogammaglobulinemia Segment is Expected to Hold Significant Market Share During the Forecast Period

Hypogammaglobulinemia is a condition in which enough gamma globulins are not produced in the blood. The major factor driving the hypogammaglobulinemia segment growth includes a significant increase in the prevalence of hypogammaglobulinemia disorders across the globe.

Globally, COVID-19 has become the greatest health challenge. Patients with cancer, especially hematologic malignancies are at high risk for COVID-19 infection. For instance, according to a research article by Sukru Cekic et al., published in Journal of Clinical Immunology 2021, protective measures against COVID-19 infection were high in primary immunodeficiencies (PIDs) patients with hypogammaglobulinemia receiving Ig replacement therapy. Moreover, female patients with primary immunodeficiencies and hypogammaglobulinemia, have increased concern about COVID-19 infection.

Hypogammaglobulinemia is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs) and invasive pneumococcal disease (IPD). According to a research study by Juthaporn Cowan et al., published in Clinical Infectious Diseases Journal 2017, as per study results the high and low estimates of prevalence of hypogammaglobulinemia was found to be 31.6% and 13.5%. in Canada. In addition, hypogammaglobulinemia was present in at least 13.5% of invasive pneumococcal disease (IPD) cases. Secondary hypogammaglobulinemia is especially common in cases with hematological malignancy and invasive pneumococcal disease (IPD).

According to a research study by Namrata Singh et al., publsihed in British Society for Haematology Journal 2020, high prevalence of hypogammaglobulinemia was found in newly diagnosed, treatment naive chronic lymphocytic lymphoma (CLL) patients. Patients with a low IgA or IgE were associated with higher stage chronic lymphocytic lymphoma (CLL).

Furthermore, hypogammaglobulinemia can be observed at extremes of age which was reported in the elderly population. In adults, Hypogammaglobulinemia may be seen in hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). Thus, increasing prevalence of elderly population along with hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) is expected to drive the segment growth over the forecast period.

North America is Expected to Dominate the Immunoglobulin Market Over the Forecast Period

The major factors driving the market growth in the North America region include rising healthcare expenditure, a growing level of consciousness for the products involved in the treatment of immunodeficiency disorders, and increasing inclination of clinicians towards immunodeficiency therapies.

In the United States, the impact of COVID-19 on the immunoglobulin market is positive as there have been increasing research studies on immunoglobulins as an effective therapy in the treatment of COVID-19. For instance, according to the National Clinical Trial (NCT) Registry, as of 9th March 2021, in the United States, there was around 50 immunoglobulin based ongoing clinical trials across different phases of development which shows a positive impact on the market as this can lead to the development of new effective therapy for COVID-19 in near future.

The market players in the United States adopted various strategies such as product launches, developments, collaborations, mergers, and acquisitions in order to increase market share. For instance, in July 2019, ADMA Biologics, Inc., received approval from United States Food and Drug Administration (FDA) for license transfer of BIVIGAM from Biotest Pharmaceuticals Corporation which began the commercial sales of the product.

Furthermore, in April 2019, ADMA Biologics, Inc., received approval from United States Food and Drug Administration (FDA) for ASCENIV, a novel intravenous immuneglobulin in the treatment of primary humoral immunodeficiency disease. Thus, owing to above mentioned factors it is expected to drive market growth over the forcast period.

Competitive Landscape

The Immunoglobulin Market is moderately competitive. The key manufacturers are found to offer technologically advanced techniques and platforms for a better understanding of disease biology and the introduction of novel therapeutics. Some of the global immunoglobulin market players are Baxter International Inc., CSL Ltd., Octapharma AG, Kedrion Biopharma Inc, Grifols S.A, Biotest AG, and others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Prevalence of Immunodeficiency Diseases
    • 4.2.2 Increase in Adoption of Immunoglobulin
    • 4.2.3 Growing Research and Development Activities
  • 4.3 Market Restraints
    • 4.3.1 Stringent Government Regulations
    • 4.3.2 High Cost of Therapy
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 IgG
    • 5.1.2 IgA
    • 5.1.3 IgM
    • 5.1.4 IgE
    • 5.1.5 IgD
  • 5.2 By Mode of Delivery
    • 5.2.1 Intravenous Mode of Delivery
    • 5.2.2 Subcutaneous Mode of Delivery
  • 5.3 By Application
    • 5.3.1 Hypogammaglobulinemia
    • 5.3.2 Chronic Inflammatory demyelinating polyneuropathy (CIDP)
    • 5.3.3 Immunodeficiency Disease
    • 5.3.4 Myasthenia Gravis
    • 5.3.5 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States (By Product, By Mode of Delivery and By Application)
      • 5.4.1.2 Canada (By Product, By Mode of Delivery and By Application)
      • 5.4.1.3 Mexico (By Product, By Mode of Delivery and By Application)
    • 5.4.2 Europe
      • 5.4.2.1 Germany (By Product, By Mode of Delivery and By Application)
      • 5.4.2.2 United Kingdom (By Product, By Mode of Delivery and By Application)
      • 5.4.2.3 France (By Product, By Mode of Delivery and By Application)
      • 5.4.2.4 Italy (By Product, By Mode of Delivery and By Application)
      • 5.4.2.5 Spain (By Product, By Mode of Delivery and By Application)
      • 5.4.2.6 Rest of Europe (By Product, By Mode of Delivery and By Application)
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China (By Product, By Mode of Delivery and By Application)
      • 5.4.3.2 Japan (By Product, By Mode of Delivery and By Application)
      • 5.4.3.3 India (By Product, By Mode of Delivery and By Application)
      • 5.4.3.4 Australia (By Product, By Mode of Delivery and By Application)
      • 5.4.3.5 South Korea (By Product, By Mode of Delivery and By Application)
      • 5.4.3.6 Rest of Asia-Pacific (By Product, By Mode of Delivery and By Application)
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC (By Product, By Mode of Delivery and By Application)
      • 5.4.4.2 South Africa (By Product, By Mode of Delivery and By Application)
      • 5.4.4.3 Rest of Middle East and Africa (By Product, By Mode of Delivery and By Application)
    • 5.4.5 South America
      • 5.4.5.1 Brazil (By Product, By Mode of Delivery and By Application)
      • 5.4.5.2 Argentina (By Product, By Mode of Delivery and By Application)
      • 5.4.5.3 Rest of South America (By Product, By Mode of Delivery and By Application)

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Baxter international Inc.
    • 6.1.2 CSL Ltd.
    • 6.1.3 Grifols S.A
    • 6.1.4 Octapharma AG
    • 6.1.5 Kedrion Biopharma Inc.
    • 6.1.6 LFB group
    • 6.1.7 Biotest AG
    • 6.1.8 China Biologics Products, Inc
    • 6.1.9 Shire (Baxalta)
    • 6.1.10 Bayer Healthcare
    • 6.1.11 Takeda Pharmaceutical Company Limited
    • 6.1.12 Bio Products Laboratory
    • 6.1.13 Sanquin Plasma Products B.V.
    • 6.1.14 Evolve Biologics Inc
    • 6.1.15 GigaGen, Inc.
    • 6.1.16 Shanghai RAAS Blood Products Co., Ltd
    • 6.1.17 ADMA Biologics, Inc
    • 6.1.18 Johnson & Johnson (Omrix Biopharmaceuticals, Inc)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q